Since December 2019, multiple cases of novel coronavirus pneumonia (COVID-19) have
been identified in Wuhan, Hubei. With the spread of the epidemic, such cases have
also been found in other parts of China and other countries. As an acute respiratory
infectious disease, COVID-19 has been included in Class B infectious diseases prescribed
in the Law of the People's Republic of China on Prevention and Treatment of Infectious
Diseases, and managed as an infectious disease of Class A. By taking a series of preventive
control and medical treatment measures, the rise of the epidemic situation in China
has been contained to a certain extent, and the epidemic situation has eased in most
provinces, but the incidence abroad is on the rise. With increased understanding of
the clinical manifestations and pathology of the disease, and the accumulation of
experience in diagnosis and treatment, in order to further strengthen the early diagnosis
and early treatment of the disease, improve the cure rate, reduce the mortality rate,
avoid nosocomial infection as much as possible and pay attention to the spread caused
by the imported cases from overseas, we revised the Diagnosis and Treatment Protocol
for Novel Coronavirus Pneumonia (Trial Version 6) to Diagnosis and Treatment Protocol
for Novel Coronavirus Pneumonia (Trial Version 7).
I. Etiological Characteristics
The novel coronaviruses belong to the β genus. They have envelopes, and the particles
are round or oval, often polymorphic, with diameter being 60 to 140 nm. Their genetic
characteristics are significantly different from SARS-CoV and MERS-CoV. Current research
shows that they share more than 85% homology with bat SARS-like coronaviruses (bat-SL-CoVZC45).
When isolated and cultured in vitro, the 2019-nCoV can be found in human respiratory
epithelial cells in about 96 hours, however, it takes about 6 days for the virus to
be found if isolated and cultured in Vero E6 and Huh-7 cell lines.
Most of the knowledge about the physical and chemical properties of coronavirus comes
from the research on SARS-CoV and MERS-CoV. The virus is sensitive to ultraviolet
and heat. Exposure to 56°C for 30 minutes and lipid solvents such as ether, 75% ethanol,
chlorine-containing disinfectant, peracetic acid, and chloroform can effectively inactivate
the virus. Chlorhexidine has not been effective in inactivating the virus.
II. Epidemiological Characteristics
1. Source of infection
Currently, the patients infected by the novel coronavirus are the main source of infection;
asymptomatic infected people can also be an infectious source.
2. Route of transmission
Transmission of the virus happens mainly through respiratory droplets and close contact.
There is the possibility of aerosol transmission in a relatively closed environment
for a long-time exposure to high concentrations of aerosol. As the novel coronavirus
can be isolated in feces and urine, attention should be paid to feces or urine contaminated
environment that may lead to aerosol or contact transmission.
3. Susceptible groups
People are generally susceptible.
III. Pathological Changes
Pathologic findings from limited autopsies and biopsy studies are summarized below:
1. Lungs
Variable consolidation is present in the lungs.
The alveoli are filled with fluid and fibrin with hyaline membrane formation. Macrophages
and many multinucleated syncytial cells are identified within the alveolar exudates.
Type II pneumocytes show marked hyperplasia and focal desquamation. Viral inclusions
are observed in type II pneumocytes and macrophages. In addition, there is prominent
edema and congestion in the alveolar septa which are infiltrated by monocytes and
lymphocytes. Fibrin microthrombi are present. In more severely affected area, hemorrhage,
necrosis, and overt hemorrhagic infarction are seen. Organization of alveolar exudates
and interstitial fibrosis are also present.
Detached epithelial cell and mucus are present in the bronchi, sometimes mucus plugs
are seen.
Hyperventilated alveoli, interrupted alveolar interstitium, and cystic formation are
occasionally seen.
By electronic microscopy, cytoplasmic 2019-nCoV virions are observed in the bronchial
epithelium and type II pneumocytes. Immunostain reveals 2019-nCoV viral immunoreactivity
in some alveolar epithelial cells and macrophages and RT-PCR confirms the presence
of 2019-nCoV nucleic acid.
2. Spleen, hilar lymph nodes, and bone marrow
The spleen is markedly atrophic with a decreased number of lymphocytes. Focal hemorrhage
and necrosis are present. Macrophages proliferation and phagocytosis are present in
the spleen. Sparsity of lymphocytes and focal necrosis are noted in lymph nodes. CD4+
and CD8+ immunohistochemistry highlights a decreased number of T cells in the spleen
and lymph nodes. Myelopoiesis is decreased in bone marrow.
3. Heart and blood vessels
Degenerated or necrosed myocardial cells are present, along with mild infiltration
of monocytes, lymphocytes, and/or neutrophils in the cardiac interstitium. Shedding
of endothelial cells, endovasculitis, and thrombi are seen in some blood vessels.
4. Liver and gall bladder
The liver is dark-red and enlarged. Degeneration and focal necrosis of hepatocytes
are found, accompanied by infiltration of neutrophils. The sinusoids are congested.
The portal areas are infiltrated by lymphocytes and histiocytes. Microthrombi are
seen. The gallbladder is prominently distended.
5. Kidneys
The kidneys are remarkable for proteinaceous exudates in the Bowman's capsule around
glomeruli, degeneration, and shedding of renal tubules epithelial cells, and hyaline
casts. Microthrombi and fibrotic foci are found in the kidney interstitium.
6. Other organs
Cerebral hyperemia and edema are present, with degeneration of some neurons. Necrotic
foci are noted in the adrenal glands. Degeneration, necrosis, and desquamation of
epithelium mucosae of variable degree are present in the esophageal, stomach, and
bowel.
IV. Clinical Characteristics
1. Clinical manifestations
Based on the current epidemiological investigation, the incubation period is one to
14 days, mostly three to seven days.
The main manifestations include fever, fatigue, and dry cough. Nasal congestion, runny
nose, sore throat, myalgia, and diarrhea are found in a few cases. Severe patients
develop dyspnea and/or hypoxemia after one week and may progress rapidly to acute
respiratory distress syndrome, septic shock, refractory metabolic acidosis, coagulopathy,
multiple organ failure etc. It is noteworthy that for severe and critically ill patients
may only present with moderate to low fever, or even no fever at all.
Some children and neonatal patients may have atypical symptoms, presented with gastrointestinal
symptoms such as vomiting and diarrhea, or only manifested as lethargy and shortness
of breath.
The patients with mild symptoms usually do not develop pneumonia but have low fever
and mild fatigue.
Based on our experience, most patients have good prognosis and a small percentage
of patients are critically ill. The prognosis for the elderly and patients with chronic
underlying diseases is poorer. The clinical course of pregnant women with COVID-19
is similar to that of non-pregnant patients of the same age. Symptoms in children
are relatively mild.
2. Laboratory tests
General findings
In the early stages of the disease, peripheral WBC count is normal or decreased and
the lymphocyte count is decreased. Some patients have elevated liver enzymes, lactate
dehydrogenase (LDH), muscle enzymes and myoglobin. Elevated troponin is seen in some
critically ill patients. Most patients have elevated C-reactive protein and erythrocyte
sedimentation rate and normal procalcitonin. In severe cases, D-dimer increases and
peripheral blood lymphocytes progressively decrease. Severe and critically ill patients
often have elevated inflammatory factors.
Pathogenic and serological findings
(1)
Pathogenic findings: Novel coronavirus nucleic acid can be detected in nasopharyngeal
swabs, sputum, lower respiratory tract secretions, blood, feces, and other specimens
using RT-PCR and/or NGS methods. It is more accurate if specimens are obtained from
lower respiratory tract (sputum or air tract extraction). The specimens should be
submitted for testing as soon as possible after collection.
(2)
Serological findings: COVID-19 virus specific IgM becomes detectable around 3–5 days
after onset; IgG reaches a titration of at least 4-fold increase during convalescence
compared with the acute phase.
3. Chest imaging
In the early stage, imaging shows multiple small patchy shadows and interstitial changes,
more apparent in the peripheral zone of lungs. As the disease progresses, imaging
shows multiple ground glass opacities and infiltration in both lungs. In severe cases,
pulmonary consolidation may occur. However, pleural effusion is rare.
V. Case Definitions
1. Suspect cases
Considering both the following epidemiological history and clinical manifestations:
1.1 Epidemiological history
1.1.1 History of travel to or residence in Wuhan and its surrounding areas, or in
other communities where cases have been reported within 14 days prior to the onset
of the disease;
1.1.2 In contact with novel coronavirus infected people (with positive results for
the nucleic acid test) within 14 days prior to the onset of the disease;
1.1.3 In contact with patients who have fever or respiratory symptoms from Wuhan and
its surrounding area, or from communities where confirmed cases have been reported
within 14 days before the onset of the disease; or
1.1.4 Clustered cases (2 or more cases with fever and/or respiratory symptoms in a
small area such families, offices, schools etc within 2 weeks).
1.2 Clinical manifestations
1.2.1 Fever and/or respiratory symptoms;
1.2.2 The aforementioned imaging characteristics of COVID-19;
1.2.3 Normal or decreased WBC count, normal or decreased lymphocyte count in the early
stage of onset.
A suspect case has any of the epidemiological history plus any two clinical manifestations
or all three clinical manifestations if there is no clear epidemiological history.
2. Confirmed cases
Suspect cases with one of the following etiological or serological evidences:
2.1 Real-time fluorescent RT-PCR indicates positive for new coronavirus nucleic acid;
2.2 Viral gene sequence is highly homologous to known new coronaviruses.
2.3 COVID-19 virus specific IgM and IgG are detectable in serum; COVID-19 virus specific
IgG is detectable or reaches a titration of at least 4-fold increase during convalescence
compared with the acute phase.
VI. Clinical Classification
1. Mild cases
The clinical symptoms were mild, and there was no sign of pneumonia on imaging.
2. Moderate cases
Showing fever and respiratory symptoms with radiological findings of pneumonia.
3. Severe cases
Adult cases meeting any of the following criteria:
(1)
Respiratory distress (≥30 breaths/min);
(2)
Oxygen saturation ≤93% at rest;
(3)
Arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300 mmHg
(1 mmHg = 0.133 kPa).
In high-altitude areas (at an altitude of over 1000 meters above the sea level), PaO2/FiO2
shall be corrected by the following formula:
Cases with chest imaging that shows obvious lesion progression within 24–48 hours
>50% shall be managed as severe cases.
Child cases meeting any of the following criteria:
(1)
Tachypnea (RR ≥ 60 breaths/min for infants aged below 2 months; RR ≥ 50 BPM for infants
aged 2–12 months; RR ≥ 40 BPM for children aged 1–5 years, and RR ≥ 30 BPM for children
above 5 years old) independent of fever and crying;
(2)
Oxygen saturation ≤92% on finger pulse oximeter taken at rest;
(3)
Labored breathing (moaning, nasal fluttering, and infrasternal, supraclavicular, and
intercostal retraction), cyanosis, and intermittent apnea;
(4)
Lethargy and convulsion;
(5)
Difficulty feeding and signs of dehydration.
4. Critical cases
Cases meeting any of the following criteria:
4.1 Respiratory failure and requiring mechanical ventilation;
4.2 Shock;
4.3 With other organ failure that requires ICU care.
VII. Clinical Early Warning Indicators of Severe and Critical Cases
1. Adults
1.1 The peripheral blood lymphocytes decrease progressively;
1.2 Peripheral blood inflammatory factors, such as IL-6 and C-reactive proteins, increase
progressively;
1.3 Lactate increases progressively;
1.4 Lung lesions develop rapidly in a short period of time.
2. Children
2.1 Respiratory rate increased;
2.2 Poor mental reaction and drowsiness;
2.3 Lactate increases progressively;
2.4 Imaging shows infiltration on both sides or multiple lobes, pleural effusion or
rapid progress of lesions in a short period of time;
2.5 Infants under the age of 3 months who have either underlying diseases (congenital
heart disease, bronchopulmonary dysplasia, respiratory tract deformity, abnormal hemoglobin,
and severe malnutrition, etc.) or immune deficiency or hypofunction (long-term use
of immunosuppressants).
VIII. Differential Diagnosis
1.
The mild manifestations of COVID-19 need to be distinguished from those of upper respiratory
tract infections caused by other viruses.
2.
COVID-19 is mainly distinguished from other known viral pneumonia and mycoplasma pneumoniae
infections such as influenza virus, adenovirus and respiratory syncytial virus. For
suspect cases, efforts should be made to use methods such as rapid antigen detection
and multiplex PCR nucleic acid testing for detection of common respiratory pathogens.
3.
COVID-19 should also be distinguished from non-infectious diseases such as vasculitis,
dermatomyositis, and organizing pneumonia.
IX. Case Finding and Reporting
Health professionals in medical institutions of all types and at all levels, upon
discovering suspect cases that meet the definition, should immediately keep them in
single room for isolation and treatment. If the cases are still considered as suspected
after consultation made by hospital experts or attending physicians, it should be
reported directly online within 2 hours; samples should be collected for new coronavirus
nucleic acid testing and suspect cases should be safely transferred to the designated
hospitals immediately. People who have been in close contact with confirmed patients
are advised to perform new coronavirus pathogenic testing in a timely manner, even
though common respiratory pathogens are tested positive.
If two nucleic acid tests, taken at least 24-h apart, of an COVID-19 suspect case
are negative, and the COVID-19 virus specific IgM and IgG are negative after 7 days
from onset, the suspect diagnosis can be ruled out.
X. Treatment
1. Treatment venue determined by the severity of the disease
1.1 Suspected and confirmed cases should be isolated and treated at designated hospitals
with effective isolation, protection, and prevention conditions in place. A suspect
case should be treated in isolation in a single room. Confirmed cases can be treated
in the same room.
1.2 Critical cases should be admitted to ICU as soon as possible.
2. General treatment
2.1 Letting patients rest in bed and strengthening support therapy; ensuring sufficient
caloric intake for patients; monitoring their water and electrolyte balance to maintain
internal environment stability; closely monitoring vital signs and oxygen saturation.
2.2 According to patients’ conditions, monitoring blood routine result, urine routine
result, C-reactive protein (CRP), biochemical indicators (liver enzyme, myocardial
enzyme, renal function etc.), coagulation function, arterial blood gas analysis, chest
imaging, and cytokines detection if necessary.
2.3 Timely providing effective oxygen therapy, including nasal catheter and mask oxygenation
and nasal high-flow oxygen therapy. If possible, inhalation of mixed hydrogen and
oxygen (H2/O2: 66.6%/33.3%) can be applied.
2.4 Antiviral therapy: Hospitals can try Alpha-interferon (5 million U or equivalent
dose each time for adults, adding 2 ml of sterilized water, atomization inhalation
twice daily), lopinavir/ritonavir (200 mg/50 mg per pill for adults, two pills each
time, twice daily, no longer than 10 days), Ribavirin (suggested to be used jointly
with interferon or lopinavir/ritonavir, 500 mg each time for adults, twice or three
times of intravenous injection daily, no longer than 10 days), chloroquine phosphate
(500 mg bid for 7 days for adults aged 18–65 with body weight over 50 kg; 500 mg bid
for Days 1 & 2 and 500 mg qd for Days 3–7 for adults with body weight below 50 kg),
Arbidol (200 mg tid for adults, no longer than 10 days). Be aware of the adverse reactions,
contraindications (for example, chloroquine cannot be used for patients with heart
diseases) and interactions of the above-mentioned drugs. Further evaluate the efficacy
of those drugs currently being used. Using three or more antiviral drugs at the same
time is not recommend; if an intolerable toxic side effect occurs, the respective
drug should be discontinued. For the treatment of pregnant women, issues such as the
number of gestational weeks, choice of drugs having the least impact on the fetus,
as well as whether pregnancy being terminated before treatment should be considered
with patients being informed of these considerations.
2.5 Antibiotic drug treatment: Blind or inappropriate use of antibiotic drugs should
be avoided, especially in combination with broad-spectrum antibiotics.
3. Treatment of severe and critical cases
3.1 Treatment principle: On the basis of symptomatic treatment, complications should
be proactively prevented, underlying diseases should be treated, secondary infections
also be prevented, and organ function support should be provided timely.
3.2 Respiratory support:
3.2.1 Oxygen therapy: Patients with severe symptoms should receive nasal cannulas
or masks for oxygen inhalation and timely assessment of respiratory distress and/or
hypoxemia should be performed.
3.2.2 High-flow nasal-catheter oxygenation or noninvasive mechanical ventilation:
When respiratory distress and/or hypoxemia of the patient cannot be alleviated after
receiving standard oxygen therapy, high-flow nasal cannula oxygen therapy or non-invasive
ventilation can be considered. If conditions do not improve or even get worse within
a short time (1–2 hours), tracheal intubation and invasive mechanical ventilation
should be used in a timely manner.
3.2.3 Invasive mechanical ventilation: Lung protective ventilation strategy, namely
low tidal volume (6–8 ml/kg of ideal body weight) and low level of airway platform
pressure (<30 cmH2O) should be used to perform mechanical ventilation to reduce ventilator-related
lung injury. While the airway platform pressure maintained ≤30 cmH2O, high PEEP can
be used to keep the airway warm and moist; avoid long sedation and wake the patient
early for lung rehabilitation. There are many cases of human-machine asynchronization,
therefore sedation and muscle relaxants should be used in a timely manner. Use closed
sputum suction according to the airway secretion, if necessary, administer appropriate
treatment based on bronchoscopy findings.
3.2.4 Rescue therapy: Pulmonary re-tensioning is recommended for patients with severe
ARDS. With sufficient human resources, prone position ventilation should be performed
for more than 12 hours per day. If the outcome of prone position ventilation is poor,
extracorporeal membrane oxygenation (ECMO) should be considered as soon as possible.
Indications include: (1) When FiO2 > 90%, the oxygenation index is less than 80 mmHg
for more than 3–4 hours; (2) For patients with only respiratory failure when the airway
platform pressure ≥35 cmH2O, VV-ECMO mode is preferred; if circulatory support is
needed, VA-ECMO mode should be used. When underlying diseases are under control and
the cardiopulmonary function shows signs of recovery, withdrawal of ECMO can be tried.
3.3 Circulatory support: On the basis of adequate fluid resuscitation, efforts should
be made to improve micro-circulation, use vasoactive drugs, closely monitor changes
in blood pressure, heart rate and urine volume as well as lactate and base excess
in arterial blood gas analysis. If necessary, use non-invasive or invasive hemodynamic
monitor such as Doppler ultrasound, echocardiography, invasive blood pressure or continuous
cardiac output (PiCCO) monitoring. In the process of treatment, pay attention to the
liquid balance strategy to avoid excessive or insufficient fluid intake.
If the heart rate suddenly increases more than 20% of the basic value or the decrease
of blood pressure is more than 20% of the basic value with manifestations of poor
skin perfusion and decreased urine volume, make sure to closely observe whether the
patient has septic shock, gastrointestinal hemorrhage, or heart failure.
3.4 Renal failure and renal replacement therapy: Active efforts should be made to
look for causes for renal function damage in critical cases such as low perfusion
and drugs. For the treatment of patients with renal failure, focus should be on the
balance of body fluid, acid and base and electrolyte balance, as well as on nutrition
support including nitrogen balance and the supplementation of energies and trace elements.
For critical cases, continuous renal replacement therapy (CRRT) can be used. The indications
include: (1) hyperkalemia; (2) acidosis; (3) pulmonary edema or water overload; (4)
fluid management in multiple organ dysfunction.
3.5 Convalescent plasma treatment: It is suitable for patients with rapid disease
progression, severe and critically ill patients. Usage and dosage should refer to
Protocol of Clinical Treatment with Convalescent Plasma for COVID-19 Patients (2nd
trial version).
3.6 Blood purification treatment: Blood purification system including plasma exchange,
absorption, perfusion, and blood/plasma filtration can remove inflammatory factors
and block “cytokine storm,” so as to reduce the damage of inflammatory reactions to
the body. It can be used for the treatment of severe and critical cases in the early
and middle stages of cytokine storm.
3.7 Immunotherapy: For patients with extensive lung lesions and severe cases who also
show an increased level of IL-6 in laboratory testing, Tocilizumab can be used for
treatment. The initial dose is 4–8 mg/kg with the recommended dose of 400 mg diluted
with 0.9% normal saline to 100 ml. The infusion time should be more than 1 hour. If
the initial medication is not effective, one extra administration can be given after
12 hours (same dose as before). No more than two administrations should be given with
the maximum single dose no more than 800 mg. Watch out for allergic reactions. Administration
is forbidden for people with active infections such as tuberculosis.
3.8 Other therapeutic measures
For patients with progressive deterioration of oxygenation indicators, rapid progress
in imaging and excessive activation of the body's inflammatory response, glucocorticoids
can be used in a short period of time (three to five days). It is recommended that
dose should not exceed the equivalent of methylprednisolone 1–2 mg/kg/day. Note that
a larger dose of glucocorticoid will delay the removal of coronavirus due to immunosuppressive
effects. Xuebijing 100 ml/time can be administered intravenously twice a day. Intestinal
microecological regulators can be used to maintain intestinal microecological balance
and prevent secondary bacterial infections.
Child severe and critical cases can be given intravenous infusion of γ-globulin.
For pregnant severe and critical cases, pregnancy should be terminated preferably
with c-section.
Patients often suffer from anxiety and fear and they should be supported by psychological
counseling.
4. Traditional Chinese medicine treatment
This disease belongs to plague in traditional Chinese medicine (TCM), caused by the
epidemic pathogenic factors. According to the different local climate characteristic
and individual state of illness and physical conditions, the following treatment Protocol
may vary. The use of over-pharmacopoeia doses should be directed by a physician.
4.1 During medical observation
Clinical manifestation 1: fatigue and gastrointestinal discomfort
Recommended Chinese patent medicines: Huoxiang Zhengqi capsules (pills, liquid, or
oral solution)
Clinical manifestation 2: fatigue and fever
Recommended Chinese patent medicines: Jinhua Qinggan granules, Lianhua Qingwen capsules
(granules), Shufeng Jiedu capsules (granules)
4.2 During clinical treatment (confirmed cases)
4.2.1 Qingfei Paidu decoction
Scope of application: It is suitable for light, moderate, and severe patients, and
can be used reasonably in combination with the actual situation of patients in the
treatment of critically ill patients.
Recommended prescription: Ma Huang (Ephedrae Herba) 9 g, Zhi Gan Cao (Glycyrrhizae
Radix) 6 g, Xing Ren (Armeniacae Semen) 9 g, Sheng Shi Gao (Gypsum fibrosum) (decocted
first) 15–30 g, Gui Zhi (Cinnamomi Ramulus) 9 g, Ze Xie (Alismatis Rhizoma) 9 g, Zhu
Ling (Polyporus) 9 g, Bai Zhu (Atractylodis macrocephalae Rhizoma) 9 g, Fu Ling (Poria)
15 g, Chai Hu (Bupleuri Radix) 16 g, Huang Qin (Scutellariae Radix) 6 g, Jiang Ban
Xia (Pinellinae Rhizoma Praeparatum) 9 g, Sheng Jiang (Zingiberis Rhizoma recens)
9 g, Zi Wan (Asteris Radix) 9 g, Kuan Dong Hua (Farfarae Flos) 9 g, She Gan (Belamcandae
Rhizoma) 9 g, Xi Xin (Asari Radix et Rhizoma) 6 g, Shan Yao (Dioscoreae Rhizoma) 12
g, Zhi Shi (Aurantii Fructus immaturus) 6 g, Chen Pi (Citri reticulatae Pericarpium)
6 g, Huo Xiang (Pogostemonis Herba) 9 g.
Suggested use: Traditional Chinese medicine decoction pieces for decocting in water.
One dose daily with half of the dose taken in the morning and half in the evening
(forty minutes after meal) with warm water. Three days make a course of treatment.
If conditions permit, the patient can take half a bowl of rice soup each time after
taking the medicine, and can take up to one bowl if the patient has a dry tongue and
is deficient in bodily fluids. (Note: If the patient does not have a fever, the amount
of gypsum should be little. If having a fever or high fever, the amount of gypsum
can be increased.) If the symptoms improve but do not fully recover, then take the
second course of treatment. If the patient has special conditions or other underlying
diseases, the prescription of the second course of treatment can be modified based
on the actual situation and the medicine should be discontinued when the symptoms
disappear.
Source of prescription: Notice on Recommending the Use of ‘Qingfei Paidu decoction’
in Treatment of COVID-19 by Integrated Traditional Chinese and Western Medicine by
the Office of the National Administration of Traditional Chinese Medicine & the General
Office of the National Health Commission. (2022 No. 22)
4.2.2 Mild cases
4.2.2.1 Cold dampness and stagnation lung syndrome
Clinical manifestations: fever, fatigue, sore body, cough, expectoration, chest tightness,
suffocation, loss of appetite, nausea, vomiting, sticky stools. Tongue has thin fat
tooth mark or is light red, and the coating is white thick rot or white greasy and
the pulse is soggy or slippery.
Recommended prescription: Sheng Ma Huang (Ephedrae Herba) 6 g, Sheng Shi Gao (Gypsum
fibrosum) 15 g, Xing Ren (Armeniacae Semen) 9 g, Qiang Huo (Notopterygii Rhizoma seu
Radix) 15 g, Ting Li Zi (Lepidii/Descurainiae Semen) 15 g, Guan Zhong (Cyrtomii Rhizoma)
9 g, Di Long (Pheretima) 15 g, Xu Chang Qing (Cynanchi paniculati Radix) 15 g, Huo
Xiang (Pogostemonis Herba) 15 g, Pei Lan (Eupatorii Herba) 9 g, Cang Zhu (Atractylodis
Rhizoma) 15 g, Yun Ling (Poria) 45 g, Sheng Bai Zhu (Atractylodis macrocephalae Rhizoma)
30 g, Jiao San Xian (Jiao Shan Zha (Crataegi Fructus), Jiao Shen Qu (Massa medicate
fermentata), and Jiao Mai Ya (Hordei Fructus germinatus)) 9 g each, Hou Po (Magnoliae
officinalis Cortex) 15 g, Jiao Bing Lang (Arecae Semen) 9 g, Wei Cao Guo (Tsaoko Fructus)
9 g, Sheng Jiang (Zingiberis Rhizoma recens) 15 g.
Suggested use: One dose daily, boiled with 600 ml water, taking 1/3 of the dose in
the morning, at noon and in the evening respectively before meal.
4.2.2.2 Dampness and heat-accumulation lung syndrome
Clinical manifestations: low or no fever, slight chills, fatigue, heavy head and body,
muscle soreness, dry cough, sore throat, dry mouth without desire of drinking much
water, or accompanied by chest tightness, no sweat or sweating, or vomiting and loss
of appetite, diarrhea, or sticky stool. The tongue is reddish, and the coating is
white, thick and greasy or thin yellow, and the pulse is slippery or soggy.
Recommended prescription: Bing Lang (Arecae Semen) 10 g, Cao Guo (Tsaoko Fructus)
10 g, Hou Po (Magnoliae officinalis Cortex) 10 g, Zhi Mu (Anemarrhenae Rhizoma) 10
g, Huang Qin (Scutellariae Radix) 10 g, Chai Hu (Bupleuri Radix) 10 g, Chi Shao (Paeoniae
Radix rubra) 10 g, Lian Qiao (Forsythiae Fructus) 15 g, Qing Hao (Artemisiae annuae
Herba) (added later) 10 g, Cang Zhu (Atractylodis Rhizoma) 10 g, Da Qjng Ye (Isatidis
Folium) 10 g, Sheng Gan Cao (Glycyrrhizae Radix) 5 g.
Suggested use: One dose daily, boiled with 400 ml water, taking half of the dose in
the morning and the other half in the evening.
4.2.3 Moderate cases
4.2.3.1 Dampness and stagnation lung syndrome
Clinical manifestations: fever, cough and scanty sputum, or yellow sputum, suffocation,
shortness of breath, bloating, and constipation. The tongue is dark red and fat; the
coating is greasy or yellow and the pulse is slippery or stringy.
Recommended prescription: Sheng Ma Huang (Ephedrae Herba) 6 g, Ku Xing Ren (Armeniacae
Semen) 15 g, Sheng Shi Gao (Gypsum fibrosum) 30 g, Sheng Yi Yi Ren (Coicis Semen)
30 g, Mao Cang Zhu (Atractylodis Rhizoma) 10 g, Guang Huo Xiang (Pogostemonis Herba)
15 g, Qing Hao Cao (Artemisiae annuae Herba) 12 g, Hu Zhang (Polygoni cuspidati Rhizoma)
20 g, Ma Bian Cao (Verbenae Herba) 30 g, Gan Lu Gen (Phragmitis Rhizoma) 30 g, Ting
Li Zi (Lepidii/Descurainiae Semen) 15 g, Hua Ju Hong (Citri grandis Exocarpium rubrum)
15 g, Sheng Gan Cao (Glycyrrhizae Radix) 10 g.
Suggested use: One dose daily, boiled with 400 ml water, taking half of the dose in
the morning and the other half in the evening.
4.2.3.2 Cold dampness lung syndrome
Clinical manifestations: low fever, submerged fever or absence of fever, dry cough,
scanty sputum, fatigue, chest tightness, stuffy and full sensation in the stomach,
or nausea. The tongue is pale or red, and the coating is white or greasy, and the
pulse is soggy.
Recommended prescription: Cang Zhu (Atractylodis Rhizoma) 15 g, Chen Pi (Citri reticulatae
Pericarpium) 10 g, Hou Po (Magnoliae officinalis Cortex) 10 g, Huo Xiang (Pogostemonis
Herba) 10 g, Cao Guo (Tsaoko Fructus) 6 g, Sheng Ma Huang (Ephedrae Herba) 6 g, Qiang
Huo (Notopterygii Rhizoma seu Radix) 10 g, Sheng Jiang (Zingiberis Rhizoma recens)
10 g, Bing Lang (Arecae Semen) 10 g.
Suggested use: One dose daily, boiled with 400 ml water, taking half of the dose in
the morning and the other half in the evening.
4.2.4 Severe cases
4.2.4.1 Plague poison and lung-closing syndrome
Clinical manifestations: fever, flushing, cough, yellowish phlegm, or blood in sputum,
wheezing, shortness of breath, tiredness, fatigue, dryness, bitterness and stickiness
in the mouth, nausea, loss of appetite, poor stool, and short urination. The tongue
is red; the coating is yellow greasy and the pulse is slippery.
Recommended prescription: Sheng Ma Huang (Ephedrae Herba) 6 g, Xing Ren (Armeniacae
Semen) 9 g, Sheng Shi Gao (Gypsum fibrosum) 15 g, Gan Cao (Glycyrrhizae Radix) 3 g,
Huo Xiang (Pogostemonis Herba) (added later) 10 g, Hou Po (Magnoliae officinalis Cortex)
10 g, Cang Zhu (Atractylodis Rhizoma) 15 g, Cao Guo (Tsaoko Fructus) 10 g, Fa Ban
Xia (Pinellinae Rhizoma Praeparatum) 9 g, Fu Ling (Poria) 15 g, Sheng Da Huang (Rhei
Radix et Rhizoma) (added later) 5 g, Sheng Huang Qi (Astragali Radix) 10 g, Ting Li
Zi (Lepidii/Descurainiae Semen) 10 g, Chi Shao (Paeoniae Radix rubra) 10 g.
Suggested use: One or two doses daily, boiled with 100–200 ml water, finish the dose(s)
in 2–4 times across the day, oral or nasal feeding.
4.2.4.2 Blazing of both qi and ying syndrome.
Clinical manifestations: Hot fever, thirst, shortness of breath, delirium and unconsciousness,
blurred vision, or spotted rash, or hematemesis, epistaxis, or convulsions in the
limbs.The tongue is crimson with little or no coating. The pulse is deep, fine and
rapid, or floating, large and rapid.
Recommended prescription: Sheng Shi Gao (Gypsum fibrosum) (decocted first) 30–60 g,
Zhi Mu (Anemarrhenae Rhizoma) 30 g, Sheng Di (Rehmanniae Radix) 30–60 g, Shui Niu
Jiao (Bubali Cornu) (decocted first) 30 g, Chi Shao (Paeoniae Radix rubra) 30 g, Xuan
Shen (Scrophulariae Radix) 30 g, Lian Qiao (Forsythiae Fructus) 15 g, Dan Pi (Moutan
Cortex) 15 g, Huang Lian (Coptidis Rhizoma) 6 g, Zhu Ye (Phyllostachys nigrae Folium)
12 g, Ting Li Zi (Lepidii/Descurainiae Semen) 15 g, Sheng Gan Cao (Glycyrrhizae Radix)
6 g.
Suggested use: 1 dose per day, decoction, first decoct Sheng Gan Cao (Glycyrrhizae
Radix) and Shui Niu Jiao (Bubali Cornu), then apply other pieces, boiled with 100–200
ml water, finish the dose(s) in 2–4 times across the day, orally or nasally.
Recommended Chinese patent medicines: Xiyanping injection, Xuebijing injection, Reduning
injection, Tanreqing injection, Xingnaojing injection. Drugs with similar efficacy
can be selected according to individual conditions, or can be used in combination
according to clinical symptoms. Traditional Chinese medicine injection can be used
in combination with TCM decoction.
4.2.5 Critical cases (Internal blockage and external desertion syndrome)
Clinical manifestations: dyspnea, asthma or mechanical ventilation needed, fainting,
irritability, sweating, cold limbs, dark purple tongue, thick greasy or dry coating,
and large floating pulse without root.
Recommended prescription: Ren Shen (Ginseng Radix) 15 g, Hei Shun Pian (Aconiti Radix
lateralis praeparata) (decocted first) 10 g, Shan Zhu Yu (Corni Fructus) 15 g, delivered
with Suhexiang Pill or Angong Niuhuang Pill.
For patients on mechanical ventilation with abdominal distention or constipation:
5–10 g of Sheng Da Huang (Rhei Radix et Rhizoma). For patients with human-machine
asynchronization: 5–10 g of Sheng Da Huang (Rhei Radix et Rhizoma) and 5–10 g of Mang
Xiao (Natrii Sulfas) while administering sedatives and muscle relaxants.
Recommended Chinese patent medicines: Xuebijing injection, Reduning injection, Tanreqing
injection, Xingnaojing injection, Shenfu injection, Shengmai injection, Shenmai injection.
Drugs with similar efficacy can be selected according to individual conditions, or
can be used in combination according to clinical symptoms. Traditional Chinese medicine
injection can be used in combination with TCM decoction.
Note: Recommended usage of TCM injections for severe and critical cases.
The use of TCM injections follows the principle of starting from a small dose and
gradually adjusting the dosage according to the instructions of the drug. The recommended
usage is as follows:
Viral infection or combined mild bacterial infection: 0.9% sodium chloride injection
250 ml plus Xiyanping injection 100 mg bid, or 0.9% sodium chloride injection 250 ml
Reduning injection 20 ml, or 0.9% sodium chloride injection 250 ml plus Tanreqing
injection 40 ml bid.
High fever with disturbance of consciousness: 250 ml of 0.9% sodium chloride injection
and 20 ml bid of Xingnaojing injection.
Systemic inflammatory response syndrome or/and multiple organ failure: 250 ml of 0.9%
sodium chloride injection and 100 ml of Xuebijing injection.
Immunosuppression: 250 ml of glucose injection with 100 ml of Shenmai injection or
20–60 ml of Shengmai injection, bid.
4.2.6 Convalescent period
4.2.6.1 Lung and spleen qi deficiency syndrome
Clinical manifestations: shortness of breath, fatigue, anorexia, nausea, fullness,
loose stool, and uneasiness. The tongue is pale and greasy.
Recommended prescription: Fa Ban Xia (Pinellinae Rhizoma Praeparatum) 9 g, Chen Pi
(Citri reticulatae Pericarpium) 10 g, Dang Shen (Codonopsis Radix) 15 g, Zhi Huang
Qi (Astragali Radix) 30 g, Chao Bai Zhu (Atractylodis macrocephalae Rhizoma) 10 g,
Fu Ling (Poria) 15 g, Huo Xiang (Pogostemonis Herba) 10 g, Sha Ren (AmomiFructus)
(added later) 6 g, Gan Cao (Glycyrrhizae Radix) 6 g.
Suggested use: One dose per day, boiled with 400 ml of water, taking half of the dose
in the morning and the other half in the evening.
4.2.6.2 Deficiency of both qi and yin syndrome.
Clinical manifestations: Fatigue, shortness of breath, dry mouth, thirst, palpitations,
sweating, poor appetite, low or no fever, dry cough, dry tongue, fine or weak pulse.
Recommended prescription: Nan Sha Shen (Adenophorae Radix) 10 g, Bei Sha Shen (Glehniae
Radix) 10 g, Mai Dong (Ophiopogonis Radix) 15 g, Xi Yang Shen (Panacis quinquefolii
Radix) 6 g, Wu Wei Zi (Schisandrae Fructus) 6 g, Sheng Shi Gao (Gypsum fibrosum) 15
g, Dan Zhu Ye (Lophatheri Herba) 10 g, Sang Ye (Mori Folium) 10 g, Lu Gen (Phragmitis
Rhizoma) 15 g, Dan Shen (Salviae miltiorrhizae Radix) 15 g, Sheng Gan Cao (Glycyrrhizae
Radix) 6 g.
Suggested use: One dose per day, boiled with 400 ml of water, taking half of the dose
in the morning and the other half in the evening.
XI. Discharge Criteria and After-discharge Considerations
1. Discharge criteria
1)
Body temperature is back to normal for more than 3 days;
2)
Respiratory symptoms improve obviously;
3)
Pulmonary imaging shows obvious absorption of inflammation;
4)
Nuclei acid tests negative twice consecutively on respiratory tract samples such as
sputum and nasopharyngeal swabs (sampling interval being at least 24 hours).
Those who meet the above criteria can be discharged.
2. After-discharge considerations
2.1 The designated hospitals should contact the primary healthcare facilities where
the patients live and share patients’ medical record, to send the information of the
discharged patients to the community committee and primary healthcare facility where
the patients reside.
2.2. After discharge, it is recommended for patients to monitor their own health status
in isolation for 14 days, wear a mask, live in well-ventilated single room if possible,
minimize close contact with family members, separate dinning, practice hand hygiene,
and avoid going out.
2.3 It is recommended for the patients to return to the hospitals for follow-up and
re-visit in two and four weeks after discharge.
XII. Patients Transportation Principles
Patients should be transported in accordance with the Work Protocol for Transfer of
the Novel Coronavirus Pneumonia Patients (Trial Version) issued by the National Health
Commission.
XIII. Nosocomial Infection Prevention and Control
Measures to prevent and control nosocomial infection should be implemented in accordance
with the requirements of the Technical Guidelines for the Prevention and Control of
Infection by the Novel Coronavirus in Medical Institutions (First Edition) and the
Guidelines on the Usage of Common Medical Protective Equipment against Novel Coronavirus
Infection (Trial Version) formulated by the National Health Commission.
The General Office of National Health Commission
Office of National TCM Administration
Printed and distributed on March 3, 2020
The “Diagnosis and Treatment Plan for COVID-2019 (Tentative Sixth Edition)” is available
at (Supplemental Material).
Disclaimer
The material was translated through WHO Representative Office in China and the contents
are the sole responsibility of the original authors.
Supplementary Material
Supplemental Digital Content